CTI BioPharma Corp - Company Profile
Powered by 
All the data and insights you need on CTI BioPharma Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date CTI BioPharma Corp Strategy Report
- Understand CTI BioPharma Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
CTI BioPharma Corp Clinical Trials
Determine CTI BioPharma Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.
A sample of CTI BioPharma Corp Clinical Trials data
| Trial Title | Trial Identifier | Drug Name | Therapy Area | Indication | Trial Phase | Trial Status | Sponsor |
|---|---|---|---|---|---|---|---|
| Deserunt mollit sunt Lorem | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Pfizer Inc |
| A Randomized, Single-dose, Three-treatment, Six-sequence, Three-period Crossover Study of the PK And Sources of Variability of Pacritinib after Oral Administration to Healthy Subjects under Fasted Conditions | GDCT0467503 | pacritinib | Immunology; Infectious Disease; Oncology | Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy; Chronic Myelomonocytic Leukemia (CMML); Colorectal Cancer; Coronavirus Disease 2019 (COVID-19); Cutaneous T-Cell Lymphoma; Graft Versus Host Disease (GVHD); Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma); Mantle Cell Lymphoma; Mycosis Fungoides; Myelofibrosis; Non-Hodgkin Lymphoma; Peripheral T-Cell Lymphomas (PTCL); Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF); Post-Polycythemia Vera Myelofibrosis (PPV-MF); Sezary Syndrome | Phase II | Completed | CTI BioPharma Corp |
| Study to Evaluate the Safety, Tolerability, and PK of Pacritinib | GDCT0453893 | pacritinib | Gastrointestinal | Liver Failure (Hepatic Insufficiency) | Phase I | Planned | CTI BioPharma Corp |
| Phase II Study: An Open-label, Randomized, Phase II Dose-finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib | GDCT0420204 | pacritinib | Oncology | Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF); Post-Polycythemia Vera Myelofibrosis (PPV-MF) | Phase II | Completed | CTI BioPharma Corp |
Feature
GlobalData’s Clinical Trials database (CTDB) is a highly comprehensive source of Clinical Trials.
The database covers planned, ongoing, completed and terminated/suspended/withdrawn clinical trials.
Clinical Trials database provides intelligence on global clinical trials for all indications. The data is sourced from:
- 250+ clinical trial registries
- 200+ scientific and investor conferences, company pipelines, press releases, and SEC filings.
Benefit
The Clinical Trials database collects information on various parameters to provide a Clinical Trial overview as well as Clinical Trial details, Drug details, Patient details, Trial Results, Location(s)/Sponsor(s) and Contact Detail(s).
Access:
- Detailed trial information.
- Drug information.
- Patient information, including inclusion and exclusion criteria.
- Trial results, as reported in the public domain.
- Biomarkers used for patient stratification/selection & outcome measures.
- Enrolment parameters.
- Investigators involved in clinical trials.
- Trials sites and locations.
- Contact information.
Value
Competitive Activity – keep an eye on planned or ongoing trials, as well as the trials currently recruiting and who is sponsoring them.
Geographic Analysis - see where trials are being run.
Trend Analysis - view top sponsors, indications, phase, status and more with Trial Analytics.
Find information on trials contacts, as well as Site and Investigator information.
Get information on trial successes and failures.
Get intelligence on CROs engaged in clinical trials.
Use as a business development tool for CROs.
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer